Related Experiment Video

Updated: Mar 2, 2026

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants
15:49

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

2.0K

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An

Jordan J Feld1, Alnoor Ramji2, Stephen D Shafran3

  • 1Toronto Centre for Liver Disease, University of Toronto, Ontario.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|May 24, 2017
PubMed

Insights

Treatment with ledipasvir-sofosbuvir and ribavirin achieved a high sustained virologic response (SVR12) in treatment-naive patients with genotype 3 hepatitis C virus (HCV). This regimen demonstrated good tolerability and efficacy, particularly in patients without cirrhosis.

Area of Science:

  • Hepatology
  • Virology
  • Clinical Trials

Background:

  • Genotype 3 hepatitis C virus (HCV) infection is associated with more rapid disease progression.
  • Genotype 3 HCV is less responsive to current direct-acting antiviral therapies.
  • Ledipasvir and sofosbuvir are direct-acting antivirals used in HCV treatment.

Purpose of the Study:

  • To evaluate the safety, tolerability, and efficacy of ledipasvir and sofosbuvir plus ribavirin.
  • To assess treatment outcomes in patients with genotype 3 HCV infection.
  • To determine sustained virologic response rates at 12 weeks post-treatment (SVR12).

Main Methods:

  • An open-label, multicenter trial (NCT02413593) enrolled treatment-naive patients with genotype 3 HCV.
  • All patients received 12 weeks of ledipasvir-sofosbuvir (90 mg/400 mg) plus weight-based ribavirin.
  • Sustained virologic response 12 weeks after treatment (SVR12) was the primary endpoint.

Main Results:

  • 99 of 111 (89%) patients achieved SVR12.
  • Patients without cirrhosis had a higher SVR12 rate (94%) compared to those with compensated cirrhosis (79%).
  • Common adverse events included fatigue (51%), headache (36%), and nausea (23%). No treatment-emergent resistance mutations were observed.

Conclusions:

  • 12 weeks of ledipasvir-sofosbuvir plus ribavirin is effective in treatment-naive patients with genotype 3 HCV.
  • The regimen demonstrated a high SVR rate, especially in patients without cirrhosis.
  • The treatment was generally safe and well-tolerated.
Abstract

Keywords:
NS5ANS5Bgenotype 3 hepatitis C virus

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.0K
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
670
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
404
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
15.1K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
439